MBX (MBX Biosciences) Other Current Liabilities: $2.33 Mil (As of Mar. 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $55.84
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Other Current Liabilities?

MBX Biosciences MBX -0.09% 12 Other Current Liabilities is $2.33 Mil as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

MBX Biosciences's other current liabilities for the quarter that ended in Mar. 2026 was $2.33 Mil.

MBX Biosciences's quarterly other current liabilities increased from Sep. 2025 ($2.78 Mil) to Dec. 2025 ($4.32 Mil) but then declined from Dec. 2025 ($4.32 Mil) to Mar. 2026 ($2.33 Mil).

MBX Biosciences's annual other current liabilities increased from Dec. 2023 ($1.37 Mil) to Dec. 2024 ($2.32 Mil) and increased from Dec. 2024 ($2.32 Mil) to Dec. 2025 ($4.32 Mil).

MBX Biosciences Other Current Liabilities Related Terms

MBX Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Other Current Liabilities Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
1.13 1.37 2.32 4.32

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 2.14 2.78 4.32 2.33
MBX
12GF Score
MBX Biosciences Inc MBX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.33 Mil mean?
MBX Biosciences (MBX) has a Other Current Liabilities of $2.33 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MBX Biosciences.
Is MBX Biosciences' Other Current Liabilities too high?
MBX Biosciences' current Other Current Liabilities is $2.33 Mil. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Other Current Liabilities compare to SLS and TRVI?
MBX Biosciences' Other Current Liabilities of $2.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MBX Biosciences. MBX Biosciences's current Other Current Liabilities is $2.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Other Current Liabilities of $2.33 Mil. The current Other Current Liabilities is $2.33 Mil. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Other Current Liabilities is $2.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$55.84
Price